SCHEDULE: FMR LLC Discloses Stake in Soleno Therapeutics

FMR LLC and Abigail P. Johnson have reported a significant beneficial ownership stake of 11.2% in Soleno Therapeutics Inc. as of March 31, 2026.

Summary

• FMR LLC and Abigail P. Johnson have filed a Schedule 13G, indicating beneficial ownership of 5,768,409.61 shares of Soleno Therapeutics Inc. common stock.
• This ownership represents 11.2% of the class of securities.
• The filing is an amendment (Amendment No. 2) to a previous filing, with the event date requiring this statement being March 31, 2026.
• FMR LLC is identified as a 'HC' (likely Holding Company or similar) type of reporting person, while Abigail P. Johnson is identified as an 'IN' (likely Investor) type.
• The filing confirms that FMR LLC and its subsidiaries, along with Abigail P. Johnson, are jointly filing this statement.
• Several entities, including FIAM LLC, Fidelity Institutional Asset Management Trust Company, Fidelity Management & Research Company LLC, and Strategic Advisers LLC, are listed as entities that beneficially own 5% or greater of the security class, operating under the 'FMR Reporters' umbrella.
• Abigail P. Johnson's role as Director, Chairman, and CEO of FMR LLC is noted, along with the Johnson family's predominant ownership of Series B voting common shares of FMR LLC, representing 49% of its voting power.
• A shareholders' voting agreement among Series B shareholders means that members of the Johnson family may be deemed to form a controlling group with respect to FMR LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports ownership stakes rather than company performance or strategic changes.

Positives

• FMR LLC and Abigail P. Johnson have disclosed a substantial beneficial ownership stake, indicating confidence or investment interest in Soleno Therapeutics Inc.
• The filing clarifies the reporting structure and the involvement of various FMR-affiliated entities in the ownership.

Negatives

• The filing does not contain specific financial performance data for Soleno Therapeutics Inc., as it is a Schedule 13G disclosure of beneficial ownership, not an earnings report.

Risks

• The filing does not explicitly mention any risks related to Soleno Therapeutics Inc.'s business operations or the investment itself.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Soleno Therapeutics Inc.'s future performance.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that significant filings by major institutional investors like FMR LLC can signal increased institutional interest or a strategic shift in a company's investor base, potentially impacting market perception and liquidity for Soleno Therapeutics Inc.

Stakeholder Impact

• Shareholders: The increased institutional ownership by a major entity like FMR LLC could be perceived positively, potentially leading to greater analyst coverage and market stability.
• Management: The filing confirms FMR LLC's non-control-seeking investment approach, which may provide reassurance to Soleno Therapeutics Inc.'s management.

Next Steps

• Continued monitoring of FMR LLC's ownership stake in Soleno Therapeutics Inc. for any future changes or disclosures.

Key Dates

Keywords

Soleno Therapeutics Inc, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Investment, SEC Filing, Fidelity